Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125264801 | 12526480 | 1 | I | 2016 | 20160524 | 20160705 | 20160705 | PER | US-ASTRAZENECA-2016SE56571 | ASTRAZENECA | 86.00 | YR | F | Y | 81.60000 | KG | 20160705 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125264801 | 12526480 | 1 | SS | ATENOLOL. | ATENOLOL | 1 | Oral | 0 | |||||||||||
| 125264801 | 12526480 | 2 | PS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | U | U | 21366 | TABLET | ||||||||
| 125264801 | 12526480 | 3 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | U | U | 21366 | TABLET | ||||||||
| 125264801 | 12526480 | 4 | C | LASIX GENERIC | 2 | Oral | 0 | ||||||||||||
| 125264801 | 12526480 | 5 | C | POTASSIUM | POTASSIUM | 1 | Oral | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125264801 | 12526480 | 1 | Blood pressure decreased |
| 125264801 | 12526480 | 2 | Coronary artery disease |
| 125264801 | 12526480 | 3 | Coronary artery disease |
| 125264801 | 12526480 | 4 | Diuretic therapy |
| 125264801 | 12526480 | 5 | Supplementation therapy |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125264801 | 12526480 | Arthritis | |
| 125264801 | 12526480 | Body height decreased | |
| 125264801 | 12526480 | Bone pain | |
| 125264801 | 12526480 | Cardiac failure congestive | |
| 125264801 | 12526480 | Coronary artery disease | |
| 125264801 | 12526480 | Erythema | |
| 125264801 | 12526480 | Gait disturbance | |
| 125264801 | 12526480 | Intentional product misuse | |
| 125264801 | 12526480 | Joint swelling | |
| 125264801 | 12526480 | Limb injury | |
| 125264801 | 12526480 | Muscle spasms | |
| 125264801 | 12526480 | Myalgia | |
| 125264801 | 12526480 | Off label use | |
| 125264801 | 12526480 | Osteoporosis | |
| 125264801 | 12526480 | Pain | |
| 125264801 | 12526480 | Peripheral swelling | |
| 125264801 | 12526480 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125264801 | 12526480 | 3 | 20160520 | 0 |